冷冻食品工业网

扫一扫关注

当前位置: 首页 » 行业资讯 » 国外资讯 » 美国 » 正文

美国FDA拟修订抗菌剂的报告要求

放大字体  缩小字体 发布日期:2012-07-31    浏览次数:421    评论:0
导读

据美国食品安全新闻网报道,目前美国食品药品管理局正在就抗菌剂的销售与分销报告的要求征求意见。

    

      据美国食品安全新闻网报道,目前美国食品药品管理局正在就抗菌剂的销售与分销报告的要求征求意见。

    美国食品药品管理局表示,目前正在考虑将《2008年兽药使用费修正案》中的部分内容纳入法规中,而且还正在审查是否还需要将其他的信息纳入新型兽药赞助商需汇报的内容当中。

    原文报道如下:

    The U.S. Food and Drug Administration is seeking comments on a proposal to make changes to the reporting requirements for antimicrobial sales and distribution.

    The agency said in a Federal Register notice that it is considering revisions to the regulation to incorporate the requirements of section 105 of the Animal Drug User Fee Amendments of 2008 (ADUFA 105). As part of that process, FDA is reviewing other reporting requirements applicable to antimicrobial new animal drug sponsors to determine whether additional information should be reported.

    "Collecting data on antimicrobial drugs used in food-producing animals will assist FDA in tracking antimicrobial use trends and examining how such trends may relate to antimicrobial resistance," read the notice.

    As the policy stands now, companies that make approved antimicrobial drugs for multiple animal species -- including both food-producing and nonfood-producing animals -- do not report sales and distribution information for each individual animal species. Drug sponsors currently only report total product sales. The information must be reported for the preceding calendar year, and include separate information for each month of the calendar year, and be submitted to FDA each year by no later than March 31. ADUFA 105 also requires the agency to publish a summary report of the antimicrobial sales data.

    The notice points out that a recent Government Accountability Office report concluded that the information collected by FDA "does not provide sufficient data needed to analyze trends in antimicrobial resistance, such as information on actual drug use in specific food-producing animal species."

    Having better data would help FDA analyze resistance trends and would better support the work of the National Antimicrobial Monitoring System (NARMS): "Improved data would enable the Agency to better correlate resistance trends data in NARMS with drug exposure, thereby providing improved information for science-based decisionmaking int he approval and monitoring of safe and effective antimicrobial drugs."

    FDA is seeking comments specifically on whether it should amend the regulation to require the submission of additional data, including (for antimicrobial drug products that are approved and labeled for more than one food-producing species) an estimate of the amount of each active antimicrobial ingredient sold or distributed for use in each species: "Specifically, comments should address how sponsors can both practically and accurately provide separate sales and distribution information for each species."

    The agency is accepting electronic or written comments until Sept. 25. To submit comments electronically, see the Federal eRulemaking Portal and follow the instructions for submitting comments.
 

    更多请见:<http://www.foodsafetynews.com/2012/07/fda-seeks-input-on-potential-changes-to-antimicrobial-drug-reporting/>

 
(文/小编)
免责声明
• 
欢迎转载,转载请注明原文出处:https://www.cnffc.cn/news/201207/31/32466.html 。如若文中涉及有违公德、触犯法律的内容,一经发现,立即删除,作者需自行承担相应责任。涉及到版权或其他问题,请及时联系我们web@cnffc.cn。
0相关评论
 

Copyright © 2011-2020 冷冻食品工业网 All Rights Reserved 中国食品工业协会冷冻冷藏食品专业委员会主办    络为科技(深圳)有限公司技术维护

粤ICP备19061761号